EUCTR2014-001956-52-IT进行中（未招募）1 期
Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study) - Tokio
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 18 years
- •Patients with hystological diagnosis of Renal Cell Carcinoma (RCC)
- •Measurable disease
- •Previous treatment with two sequences of TKIs including sunitinib followed by axitinib and pazopanib followed by sorafenib.
- •ECOG Performance Status of 0 or 1
- •All prognostic group according to Heng criteria
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •- Hemoglobin ? 10.0 g/dl
- •- Absolute neutrophil count (ANC) >1,500/mm3
- •- Platelet count ? 100,000/ml
- •- Total bilirubin = 1.5 times the upper limit of normal
- •- ALT and AST = 2.5 x upper limit of normal
- •- Alkaline phosphatase = 4 x ULN
- •- PT-INR/PTT = 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.] For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until INR is stable based on a measurement at pre-dose, as defined by the local standard of care.
- •Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- •Signed informed consent must be obtained prior to any study specific procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •Previous treatment for metastatic RCC other than pazopanib followed by sorafenib or sunitinib followed by axitinib
- •History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic).
- •History of HIV infection
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft
- •Patients with evidence or history of bleeding diasthesis
- •Patients undergoing renal dialisis
- •History of other disease, metabolic dysfunction, physical examination findings or clinical laboratory findings giving reasonable suspicion of a disease condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 2 years prior to study entry.
研究者
相似试验
已完成
不适用
Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertensiopulmonary hypertensionJPRN-UMIN000015696Hokkaido University Hospital, Internal medicine I5
终止
2 期
Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)Renal Cancer CellNCT03456401Fondazione IRCCS Istituto Nazionale dei Tumori, Milano18
招募中
不适用
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitorsmalignancies10027655cancerNL-OMON53128Antoni van Leeuwenhoek Ziekenhuis1,500
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
尚未招募
3 期
Efficacy of Rho-Kinase inhibitor in Post-operative Striate KeratopathyCTRI/2024/04/065348BLDE UNIVERSITY